Skip to content
naulon
Get started

Not checked for notices yet.

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

Sabryna Nantel, Sabryna Nantel, Benoîte Bourdin and 31 more

Frontiers in Immunology · 2022

doi:10.3389/fimmu.2022.930252

References 45

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.
    Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity · 2020
    No notice
  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.
    Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection · 2021
    No notice
  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.
    Persistent cellular immunity to SARS-CoV-2 infection · 2021
    No notice
  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.
    mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021
    No notice
  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.
    Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination · 2021
    No notice
  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.
    Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine · 2021
    No notice
  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.
    Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022 · 2022
    No notice
  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.
    Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients · 2022
    No notice
  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.
    Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes · 2022
    No notice
  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.